One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Elicio Therapeutics, Inc.
ELTX · NCM · Healthcare · Biotechnology
Current price
$1.85
52-week range
$1.44 - $16.00
Market cap
$50.12M
Balance sheet
Healthy
-32.92x Concerning
Net cash $9.33M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -774.6% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 26.2% (peer median: 28.7%).
What this company does
Elicio Therapeutics, Inc.
Elicio Therapeutics is developing new medicines that aim to train a person's own immune system to fight cancer. Their main focus is on experimental treatments for specific types of tumors identified by certain genetic mutations, with one promising candidate currently in mid-stage testing. This matters because if these treatments are successful, they could offer new hope for cancer patients who currently have limited options.
How the company got here
Elicio Therapeutics was founded in 2011, stemming from technology developed in Darrell Irvine's lab at MIT. [2] The company focuses on developing immunotherapies, which are treatments that harness the body's own immune system to fight diseases like cancer. [15] Elicio's core technology, known as the Amphiphile (AMP) platform, is designed to deliver therapeutic agents directly to the lymph nodes, which are considered the "command center" of the immune system. [18] This targeted approach aims to enhance the immune system's ability to recognize and attack cancer cells. [17] The company went public in June 2023 through a reverse merger with Angion Biomedica Corp. [2]
What it actually does
Elicio Therapeutics is a biotechnology company that develops cancer immunotherapies. [18] Instead of directly attacking cancer cells with drugs, Elicio's approach uses its proprietary Amphiphile (AMP) platform to train the immune system to fight cancer. [17] This platform works by delivering therapeutic agents directly to the lymph nodes, where immune cells are educated and activated. [18] The goal is to create a more robust and durable immune response against cancer, particularly for aggressive forms of the disease. [17] Elicio's therapies are designed to be "off-the-shelf," meaning they are not personalized for each patient, which can allow for faster manufacturing and wider availability. [7]
ELI-002
Elicio's lead product candidate is ELI-002, a type of immunotherapy designed to target cancers driven by mutations in the KRAS gene. [3] The KRAS gene is a common driver of many human cancers, including pancreatic and colorectal cancers. [3, 16] ELI-002 is built using Elicio's AMP technology and consists of modified peptide antigens that target these specific KRAS mutations. [3] It is designed to be administered as an "off-the-shelf" treatment, meaning it can be manufactured and used without needing to be customized for each individual patient. [7] The company is investigating ELI-002 in clinical trials for patients with pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), particularly those who have completed standard treatments but still have a high risk of the cancer returning. [3, 16]
ELI-007
Elicio is developing ELI-007, another immunotherapy candidate that utilizes the AMP platform. [1] This therapy is designed to target cancers driven by mutations in the BRAF gene, such as the V600E and V600K mutations, which are found in a significant percentage of BRAF-driven cancers. [1, 9] By targeting these specific mutations, ELI-007 aims to stimulate a strong T cell response against cancer cells with these genetic alterations. [1] Preclinical studies have shown that ELI-007 can generate potent and functional T cell responses, suggesting its potential in treating various solid tumors, including melanoma, colorectal cancer, and lung cancer. [1, 10] The primary indication currently being explored for ELI-007 is gastrointestinal cancer. [10]
ELI-008
ELI-008 is another investigational immunotherapy from Elicio Therapeutics, also built on the AMP platform. [1] This therapy is designed to target cancers that have mutations in the p53 tumor suppressor gene, known as p53 hotspot mutations. [1] The p53 protein plays a crucial role in controlling cell division and preventing uncontrolled tumor growth, and mutations in this gene can lead to cancer progression. [1] ELI-008 aims to generate a targeted immune response against cancer cells carrying these p53 mutations. [1] Preclinical research indicates that ELI-008 can induce strong T cell activation and tumor-antigen-specific responses, showing promise for treating a wide range of solid tumors, including melanoma, colorectal cancer, and non-small cell lung cancer. [1]
What management is betting on now
Elicio Therapeutics is currently focusing its development efforts on advancing its lead candidate, ELI-002, through clinical trials, particularly for pancreatic and colorectal cancers driven by KRAS mutations. [3, 16] The company is also exploring the potential of its other pipeline candidates, ELI-007 and ELI-008, which target BRAF and p53 mutations, respectively. [1, 21] A key strategic priority is to leverage their proprietary Amphiphile (AMP) platform, which is designed to deliver immunotherapies directly to lymph nodes to enhance immune responses. [17, 18] Elicio is also shifting its focus towards developing therapies for metastatic pancreatic cancer, seeing it as a larger market with a potentially faster path to later-stage clinical trials and requiring less capital. [20] The company aims to develop effective, off-the-shelf immunotherapies that can provide durable anti-tumor responses for patients with limited treatment options. [7, 17]
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-7.27M
FY2024 Q4
$-8.79M
FY2025 Q2
$-8.95M
FY2025 Q3
$-11.09M
FY2025 Q4
$-6.81M
Revenue
—
Net income
$-8.22M
Diluted EPS
-0.43
Operating cash flow
$-8.16M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-11.82M
Diluted EPS
-0.65
Operating cash flow
$-11.64M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-7.72M
Diluted EPS
-0.45
Operating cash flow
$-6.80M
Free cash flow
$-6.81M
Fetching…
Sources
Revenue
—
Net income
$-10.08M
Diluted EPS
-0.60
Operating cash flow
$-11.09M
Free cash flow
$-11.09M
Fetching…
Sources
Revenue
—
Net income
$-10.56M
Diluted EPS
-0.66
Operating cash flow
$-8.95M
Free cash flow
$-8.95M
Fetching…
Sources
Revenue
—
Net income
$-11.21M
Diluted EPS
-0.87
Operating cash flow
$-10.12M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-14.00M
Diluted EPS
-1.07
Operating cash flow
$-8.74M
Free cash flow
$-8.79M
Fetching…
Sources
Revenue
—
Net income
$-18.84M
Diluted EPS
-1.39
Operating cash flow
$-7.27M
Free cash flow
$-7.27M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $1.85
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $9.3M - more cash than debt. Interest coverage -32.9x.
Net debt
$-9.33M
Interest coverage
-32.92x
Elicio Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 5 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ELTX
BASELINE
Elicio Therapeutics, Inc.
Total debt $14.15M Interest coverage -32.92x This is the baseline the peer rows are being compared against.
Total debt $9.44M Interest coverage -133.63x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -11.50x Neither company has much profit cushion over interest right now.
Total debt $738.68K Interest coverage -1,201.72x Neither company has much profit cushion over interest right now.
Total debt $3.75M Interest coverage -112.78x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ELTX
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -774.6% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 26.2% (peer median: 28.7%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.09x
P/B
5.11x
P/S
—
EV/EBITDA
-1.04x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-774.6%
ROA
-77.9%
Health
Liquidity and balance-sheet strength
Debt / equity
1.78x
Current ratio
2.77x
Quick ratio
2.55x
Total debt
$14.15M
Total cash
$23.48M
Growth
How the business has been compounding
Revenue TTM
$653.00K
Revenue 5Y CAGR
-91.9%
EPS TTM
-2.34
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-37.69M
Free CF TTM
$-36.97M
FCF margin
-5,661.3%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—